Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
VDRM ViaDerma, Inc. A Division of ViaDerma, Inc. , A Public Company. Breakthrough Rapid Delivery of Nutrients and Medicines ViaDerma, Inc. is a biotechnology licensing company committed to bringing new products quickly to the pharmaceutical industry through innovative research & development. ViaDerma licenses products in fields of medicine ranging from infectious diseases to stem-cell therapy. About Our Products Proprietary and Trade Secret Mechanism of Action ViaDerma's proprietary transdermal delivery system allows for rapid mass transfer of the pharmaceutical active ingredient across the skin and into the body to provide immediate localized therapy.The technology allows transfer of chemicals through the stratum corneum (outer layer of skin) with a diffusion constant which is 10,000 times higher than the diffusion constant which characterizes water movement through the stratum corneum. This enables ViaDerma to pair almost any active ingredient with the technology and provide rapid transport of the medicine right to the site of action. The first product is a broad spectrum tetracycline-based topical antibiotic is the only antibiotic in the world that kills bacteria both a physical and a chemical mechanism. All known antibiotics (other than ours) primarily use only a chemical mechanism of kill. The physical mechanism of kill is a key feature of what we call Rapid Active Ingredient Delivery System (RAIDS). One result of RAIDS is that tetracycline is carried in higher concentrations, more quickly, to and through the cell walls, where the tetracycline can become more effective than if conventional antibiotics were used. Conventional antibiotics require more time (usually prescribed for 5 to 7 days for best results), whereas our tetracycline-based products usually produce desirable results in 24 hours (or less) because of the RAIDS effect. Skin Layer Organization A second important result of RAIDS is that the topical antibiotic [b]kills all harmful Gram positive and Gram negative bacteria that have been available for testing. [/b] We believe this is the world’s strongest broad-spectrum topical antibiotic available. The potential commercial impact is immense. Drug developers believe it takes much longer for bacteria to develop drug resistance to a physical kill mechanism. This is because it is relatively easy for bacteria to change their response to a chemical threat, but it takes numerous generations for bacteria to grow a new kind of cell wall structure to respond to a physical threat. Our novel approach to overcome drug resistance of antibiotics is designed to sustain the effectiveness of antibiotics and other topical drugs for many years. This gives new topical drug products a longer useful lifetime and therefore more commercial value. This technology, when licensed to larger pharmaceutical companies, may provide stronger incentive for the discovery and development of new antimicrobial drugs. In recent years, the dearth of new antibiotics has been largely due to the uncertain new-drug commercial lifetime which is diminished when bacteria develop immunity to that drug. In addition the technology can be licensed to other companies to convert existing oral drugs to transdermal medications extending the profitably of the existing drug. APPLICATIONS & USAGE We are developing products in the following fields of use; Topical antibiotics Treats all types of bacteria including MRSA, VRE and other flesh eating bacteria. Fights drug resistant bacteria. $6B/year global market. Estimated Global prevalence rate of all types of bacterial infection including pets: 2 Billion. Estimated Global prevalence rate of MRSA: 140 million. Topical toenail antifungal Acne Psoriasis Eczema Topical toenail antifungal Onychomycosis, a fungal infection of the toenails, is a major health problem. It is estimated that there are in excess of 40 million sufferers with this condition in the USA. It is a problem throughout the world. A recent European study showed that the prevalence of Onychomycosis may be as high as 26.9%. Fungal resistance can occur when the oral antifungal agents are used on a long-term basis. Topically applied antifungal drugs may work somewhat better adjunctive to surgical removal or chemical dissolution of the nail plate. Yet, this often ineffective and traumatic procedure leaves the subject without a nail for months at risk for re-infection. Given the limitations of current treatment options in this $3B market, there is a great need for a simple, nontoxic and effective alternative treatment. Estimated Global prevalence rate: 140 million. Anti-viral formula Treats symptoms of Influenza which is a$4B/ year global market: Common Estimated Global prevalence rate of Influenza: 355-1065 million. Estimated Global prevalence rate of “Bird Flu”: Very rare, about 500 cases. Estimated Global prevalence rate of “Swine Flu”: 1420 million were infected in 2009 Wound care Diabetic foot wounds. Diabetic foot Ulcers; $1.5B/year global market. 12 million people per year Contact Details ViaDerma's global headquarters is located at 8950 W. Olympic Blvd, Suite 576, Beverly Hills, CA 90211. We are currently in discussions with companies in Australia & New Zealand, India, China, and West Africa. Phone: 310.871.3996 Headlines Get Headlines for: Tuesday, August 5, 2014 ViaDerma, Inc. Announces Strategic Partnership With The Brewer GroupPR Newswire (Tue, Aug 5) Tuesday, June 10, 2014 VIADERMA INC FinancialsEDGAR Online Financials (Tue, Jun 10) Older Headlines - Most Recent Headlines --------------------------------------------------------------------------------
TetraStem, Lead Product of ViaDerma, Inc., Hopes to Slow Rates of Diabetic Amputations GlobeNewswire via CMTX - Fri Nov 07, 7:54AM CST ViaDerma, Inc. (OTCQB:VDRM), a specialty pharmaceutical company devoted to bringing new products to market, has recently released a revolutionary new wound care drug called TetraStem. TetraStem is a topical liquid tetracycline-based antibiotic that uses a patent-pending innovative transdermal delivery system that has shown success in aiding the healing of diabetic wounds and therefore preventing amputations. Diabetes is a serious medical condition that affects how the body uses blood sugar. Because glucose is vital for your cells to have enough energy, too much of it can lead to major medical problems such as amputations. In 2010, roughly 8% of the American population had diabetes, or 25.8 million people. Of those 25.8 million diagnosed diabetics, 73,000 adults had non-traumatic lower-limb amputations, according to the American Diabetes Association. TetraStem has shown success in laboratory trials and found to be 99 percent effective against all bacteria. ViaDerma believes the application of TetraStem can maximize the healing of diabetic wounds before they require amputation. "TetraStem kills infection because of the proprietary, transdermal delivery that allows TetraStem to kill bacteria chemically and physically," says CEO of ViaDerma, Dr. Christopher Otiko. "We hope that the application of TetraStem can help reduce the number of amputations from diabetic wounds, thereby saving lives and increasing people's quality of life." Authorized Shares: 150,000,000 a/o Sep 30, 2015 Outstanding Shares: 109,042,787 a/o Sep 30, 2015 Float: 18,188,076 a/o Sep 30, 2015 Par Value 0.001 ------$VDRM COULD BE THE pharmacy stock of the year. This stock could run 30,000% here's why. 1) EXTREMELY OVERSOLD and unknown 2) ONLY 150 MILLION A\S! Makes it the TINIEST FLOAT VS PRICE out of ALL pharmacy stockso in the whole country! 3) Pharmaceutical stocks have the LARGEST PERCENTAGE GAINS OUT OF ALL STOCKS IN THE MARKET on the big boards or the OTHER. 4) Unusual sudden MASSIVE increase in volume since 3/7/16 LOOK. 5) INSIDERS OWN 75 MILLION SHARES, that's right 75 MILLION! 6) WON AWARD FOR THEIR DRUG 7) STRONG HANDS HOLDING 11 million shares out of the TINY 18 million float. 8) After being silent for ages 4 JUICY FILINGS came out in September so something could be up. 9) THEY HAVE A PATENT which big boys have to be eyeing. VDRM IS A HIDDEN GOLDMINE THIS IS NOT A REGULAR PENNY STOCK. The LOWEST FLOAT vs price vs ALL PHARMA STOCKS IN THE COUNTRY. BIG BOARD OR OTC LAND. ALL OF THEM. Pharma stocks have the HIGHIGHEST EST percentage gain in big boards or penny stocks
investorshub.advfn.com/ViaDerma-Inc-V... Mijn beste aandeel wat ik ooit heb gehad en misschien wel het beste aandeel op de hele OTC. Letterlijk een verborgen goudmijn. De float op dit aandeel is deze week bijna helemaal opgekocht. Er zijn dan ook niet veel aandelen meer beschikbaar en er gaat een ware run op komen. De producten die ze hebben hebben al Awards gewonnen, waaronder de Edison Award. Ook maken ze kwartaal op kwartaal meer winst en zijn ze schuldenvrij. Is is vrijwel niemand die verkoopt en alleenmaar kopers. Lees het allemaal door zou ik zeggen en geef uw mening. groetjes Daan.
Lijkt wat te broeien. Kan hem bij degiro niet vinden helaas.
Ik heb ze via Alex aangeschaft Marco. Volgens mij is het aanbod van de giro vrij beperkt. Of misschien moet je eerst wat papieren tekenen om USA aandelen te kopen.
Nee hoor heb verder nooit problemen met amerikaanse aandelen. Maar kan hem niet vinden op naam of isin code. En voor dit geld is het nog wel een gokje waard.
Viaderma Inc (OTCMKTS:VDRM) continues to surge on new developments of entering a $3+ billion market, giving investors reason to be excited. The company just announced that it will be initiating an upcoming field trial of comparison for Onychomycosis. The stock has surged over 50% in trading today and the stock has tripled since the beginning of March. VDRM has seen a significant expansion in volume which is a bullish development. VDRM is attempting to break into the Onychomycosis market with its TetraStem liquid based antibiotic. The market size of Onychomycosis treatment is estimated to be at approximately $3.5 billion in the USA markets alone. Onychomycosis is a fungal infection of the toenails or fingernails that may involve any part of the nail itself. This infection can cause pain, distress, and deformity that could produce serious physical and occupational restrictions, as well as affect quality of life. Recently registered as a medication by the FDA, TetraStem, that is designed to treat cuts, scrapes, and burns. Viaderma Inc (OTCMKTS:VDRM) introduced an upcoming trial that is expected to take place in the Springtime. The study will feature their leading product, TetraStem. In the trials patients will receive both treatments at 90-day, six months, nine months, and one year lapses of time. Previously used as an off-label treatment for Onychomycosis with proven results, ViaDerma believes that TetraStem will serve as a possible more effective and more affordable option than other leading brands. The company’s flagship product TetraStem has been seen in private off-label practice to hold an 86% success rate after only 12 weeks of use. Current competition has only seen an 18% success rate, requiring 48 weeks of patient use. Not only are these differences staggering, but to add to that, a bottle of TetraStem retails for only $39.99, whereas the same size has been sold for more than $500 through other brands. VDRM was founded in 2014 by Dr. Christopher Otiko, ViaDerma, Inc. (VDRM) is a publicly traded specialty pharmaceutical company committed to bringing new products to market and licensing its innovative technology to current leaders in the pharmaceutical industry in a wide variety of therapeutic areas. ViaDerma’s lead product, TetraStem, uses an innovative transdermal delivery method to apply almost any active ingredient to a topical drug. This patent-pending dual carrier transdermal technology may be applied in products within the medical and cosmetic markets.
Lijkt op een aanhoudende breakout naar $0,20
Heb ze ook gekocht voor de gok. 140K .
mks schreef op 5 april 2016 23:16 :
Heb ze ook gekocht voor de gok.
140K .
Top! kijken of je vandaag al op winst kan komen, na een kleine consolidatie dag gister.
warren buffetttt schreef op 7 april 2016 07:49 :
[...]
Top! kijken of je vandaag al op winst kan komen, na een kleine consolidatie dag gister.
Hoppa de helft eraf,niet zo'n goede gok dus. Er zit een zekere Dutchdaan op I-Hub die aangeeft de CEO aan de telefoon te hebben gehad waarna hij zijn aandelen heeft verkocht ivm niet vertrouwenswekkend Dit ben jij toch niet ?
Het is echt geen gok. Zeer gezond bedrijf. Een voorgangerbedrijf van dezelfde branche (Owcp) ging van september'16 tot nu van 0,003 naar 0,95$.Stijgingen van 0,35$ per dag en meer waren er bij. Een verdere voorganger (Axim)heeft al de 19$ aangeraakt nu even teruggevallen naar 13$. Dan te bedenken dat deze bedrijven nog geen winst maken. Owcp vorig jaar een verlies van 1,7 miljoen. Viaderma al in de winst zoals hiervoor al aangegeven. Potentie is echt enorm. Reden waarom deze bedrijven zo gewild zijn is dat ze op het juiste moment de markt bedienen bij een terugtrekkend verbod op marijuana. Viaderma geeft ook een indicatie per ziektebestrijding van de marktpotentie met een te verwachten omzet in de miljarden. Dan blijkt de potentie!!!! Viaderma is de markt aan het veroveren in Amerika maar is nu al reeds bezig hun produkten te gaan verkopen in alle werelddelen. Nog meer potentie dus die gestadig zal groeien jaarlijks. Mooi vasthouden u gaat heel rijk worden.
Begint op stoom te komen :)
Momenteel 66 procent + na goed nieuws schow
Nog iemand die dit aandeel volgt ,Heb mijn twijfels omtrent hun patenten ???
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Indices
AEX
874,02
-0,09%
EUR/USD
1,0698
-0,04%
FTSE 100
8.040,38
-0,06%
Germany40^
18.086,70
-0,01%
Gold spot
2.316,03
0,00%
NY-Nasdaq Composite
15.712,75
+0,10%
Stijgers
Dalers